November 27, 2012 – Although litigation over Pradaxa internal bleeding only started months ago, patients should be hopeful that cases are moving forward quickly.
Judge David Herndon, who was tasked with overseeing the cases after they were moved to federal court, recently ordered that German drug maker Boehringer Ingelheim will have to produce all evidence it possesses disputing injury claims by December 17th.
Experts believe the documents provided by the company could number into the millions, however, this will give counsel for those injured after taking the drug critical information into the early clinical trials and safety testing of the drug.
Many expect the evidence to show that Boehringer Ingelheim knew that Pradaxa had serious health risks and no antidote for internal bleeding, neither of which were properly provided to patients.
In it’s latest report, the Judicial Panel on MultiDistrict Litigation indicated that the number of Pradaxa lawsuits has increased 50% since early September.
In October, the Institute for Safe Medicine Practices reported that consumer complaints for drug complications has increased 90% since 2008. They also pointed to two medications, Pradaxa and Chantix, as being responsible for 37% of the increase.
Anyone affected by internal bleeding after taking Pradaxa should speak with a lawyer as soon as possible about the ongoing litigation and their own legal options. Federal drug injury cases can be very complex and specialized, therefore, the Drug Risk Resource Center only recommends lawyers who are already handling Pradaxa lawsuits.
For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, contact us today.